J Korean Med Sci.  2001 Dec;16(Suppl):S42-S53. 10.3346/jkms.2001.16.S.S42.

Chemoprevention of Mammary, Cervix and Nervous system Carcinogenesis in Animals using Cultured Panax ginseng Drugs and Preliminary Clinical Trials in Patients with Precancerous Lesions of the Esophagus and Endometrium

Affiliations
  • 1Group of Cancer Chemoprevention, N.N. Petrov, Research Institute of Oncology of the Ministry of Health of the Russian Federation, St. Petersburg, Russia.
  • 2Russia Laboratory of Immunology, N.N. Petrov Research Institute of Oncology of the Ministry of Health of the Russian Federation, St. Petersburg, Russia.
  • 3Department for Study of the Esophagus Cancer, Karakalpak's Research Institute of Clinical and Experimental Medicine, Nukus.
  • 4Uzbekistan Chair of Obstetrics and Gynecology, Chernovtsy's State Medical Institute, Chernovtsy.
  • 5Ukraine Chair of Physiology, State Chemical-Pharmaceutical Academy, St. Petersburg, Russia.

Abstract

The anticarcinogenic effects and mechanisms of the biotechnological drugs of Panax ginseng C.A. Meyer cultivated in Russia, bioginseng, panaxel and panaxel- 5, were studied. Bioginseng was produced from a tissue culture of ginseng root cultured on standard medium, whereas panaxel and panaxel-5 were produced from ginseng tissue root cultures using standard mediums enriched with 2-carboxyethylgermanium sesquioxide and 1-hydroxygermatran-monohydrate respectively. All three ginseng drugs inhibited the development of mammary tumors induced by intramammary injections of N-methyl-N-nitrosourea (MNU) in rats, the development of the brain and spinal cord tumors induced by transplacental administration of N-ethyl-N-nitrosourea (ENU) in rats, and the development of uterine, cervical and vaginal tumors induced by intravaginal applications of 7,12-dimethylbenz(a)anthracene (DMBA) in mice. The ginseng drugs induced the cytotoxic activity of macrophages in mice, enhanced T-lymphocyte rosette formation in guinea pigs exposed to cyclophosphamide, and stimulated the production of thyroid hormones in rats. These mechanisms may contribute to the anticarcinogenic action of the ginseng drugs. The organic germanium compounds present in panaxel and panaxel-5 did not potentiate the anticarcinogenic or immuno- stimulatory effects as much as biogeinseng. Preliminary clinical trials with panaxel and bioginseng were carried out in patients with precancerous lesions of the esophagus and endometrium. Panaxel was found to have a strong therapeutic effect in patients suffering from chronic erosive esophagitis. Bioginseng induced the regression of adenomatous-cystic hyperplasia of the endometrium in some patients. Thus, we conclude that the drugs of ginseng appear to hold considerable promise for future cancer chemoprevention.

Keyword

Chemical Carcinogenesis; Anticarcinogenic Agents; Ginseng; Precancerous Conditions; Chemoprevention

MeSH Terms

Adenocarcinoma/chemically induced/prevention & control
Adult
Animal
Antineoplastic Agents, Phytogenic/*therapeutic use
Cells, Cultured
Cervix Neoplasms/chemically induced/prevention & control
Clinical Trials
Cytotoxicity Tests, Immunologic
Disease Models, Animal
Endometrial Neoplasms/pathology/prevention & control
Endometrium/pathology
Esophageal Neoplasms/pathology/prevention & control
Esophagus/pathology
Estradiol/blood
Female
Fibroadenoma/chemically induced/prevention & control
Human
Macrophages, Peritoneal/cytology/immunology
Male
Mammary Neoplasms, Experimental/chemically induced/prevention & control
Mice
Mice, Inbred C57BL
Neoplasms, Experimental/chemically induced/*prevention & control
Nervous System Neoplasms/chemically induced/prevention & control
Panax/*metabolism
Precancerous Conditions/pathology/*prevention & control
Rats
Tissue Culture
Uterine Neoplasms/chemically induced/prevention & control
Vaginal Neoplasms/chemically induced/prevention & control
Full Text Links
  • JKMS
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr